Table 1. Baseline characteristicsa.
| Patients | Controls | Wilcoxon TST / Fisher’s ET | Cut-off | ||||
|---|---|---|---|---|---|---|---|
| Group in risk | Fisher’s ET | Odds Ratio | |||||
| P-value | P-value | Value | Confidence Interval | ||||
| n | 58 (F 43; M 15) | 31 (F 21; M 10) | n.s. | - | - | - | - |
| Age at clinical onset (y) | 33.5 ± 10.5 | 33.8 ± 11.2 | n.s. | - | - | - | - |
| OCGB positivity | 55 (95%) | 0 | <0.0001 | positive | - | 568.3b | 56.7–5700.4 |
| IgM calc positivity | 18 (31%) | 0 | 0.0004 | positive | - | 13.5b | 1.7–103.4 |
| OCMB positivity | 21 (36%) | 1 (3%) | 0.0005 | positive | - | 17.3 | 2.2–134.0 |
| IndexIL-2 | 0.24 ± 0.10 | 0.31 ± 0.12 | 0.0157 | <0.34 | 0.0063 | 4.5 | 1.6–13.2 |
| IndexIL-6 | 0.41 ± 0.37 | 0.74 ± 1.41 | n.s. | - | - | - | - |
| IndexIL-10 | 0.22 ± 0.12 | 0.29 ± 0.14 | 0.0143 | <0.23 | 0.0053 | 4.3 | 1.6–11.6 |
| IndexCHI3L2 | 2.45 ± 3.72 | 2.01 ± 3.46 | n.s. | - | - | - | - |
| pNfH in CSF (pg/ml) | 263.9 ± 377.3 | 432.4 ± 1447.5 | n.s. | - | - | - | - |
| pNfH in serum (pg/ml) | 24.2 ± 21.7 | 20.7 ± 17.2 | n.s. | - | - | - | - |
TST = two sample test; ET = exact test;— = does not apply; F = female; M = male; n.s. = non-significant; y = years; m = months; DMD = disease modifying drugs; EDSS = Expanded Disability Status Scale; OCGB = IgG oligoclonal bands; IgM calc = calculated IgM intrathecal synthesis; OCMB = IgM oligoclonal bands; IL-2 = interleukin 2; IL-6 = interleukin 6; IL-10 = interleukin 10; CHI3L2 = chitinase 3-like 2 protein; pNfH = phosphorylated neurofilament heavy chains; CSF = cerebrospinal fluid.
aValues in the table are absolute counts or means ± standard deviation unless otherwise stated.
bValues of odds ratio for OCGB and IgM calc are based on statistical simulation (0 patients in control group).